

## Unexpected transformations of an azoxyquinoxaline

Annamária Molnár,<sup>a,b</sup> Sándor Boros,<sup>a</sup> Kálmán Simon,<sup>a</sup> István Hermeecz,<sup>a,b\*</sup> and Csaba Gönczi<sup>a</sup>

<sup>a</sup>*Chinoin Ltd, Tó utca 1-5, H-1045 Budapest, Hungary*

<sup>b</sup>*Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Budafoki út 8, H-1111 Budapest, Hungary*

*E-mail: [Istvan-EXT.Hermeecz@sanofi-aventis.com](mailto:Istvan-EXT.Hermeecz@sanofi-aventis.com)*

---

### Abstract


Treatment of *N,N'*-di(quinoxalin-2-yl)diazene *N*-oxide **3** with strong acids did not give the expected Wallach-type hydroxylated product, but the first representative of the pentacyclic imidazo[1,2-*a*:4,5-*b'*]diquinoxaline system **5**. Heating in a weaker acid or neat furnished 1-(quinoxalin-2-yl)quinoxalin-2(1*H*)-one **12**. The structures of these products were confirmed by independent synthesis and NMR experiments or X-ray crystallography.

**Keywords:** Nitrogen heterocycles, azoxy compound, thermal transformation, acid catalyzed transformation, rearrangement

---

### Introduction


Treatment of azoxybenzene **1** and its derivatives with certain strong acids is known to result in the corresponding hydroxyazobenzene **2** (Scheme 1).<sup>1</sup> This rearrangement, discovered by Wallach, was named after him.<sup>2</sup> The products of the Wallach transformation have been found to depend on the reaction conditions: the hydroxyl group generally appears in a *para* position, though the application of photochemical<sup>3</sup> or Lewis acid-catalysed<sup>4</sup> reactions or blocking of both *para* positions<sup>5</sup> leads to the formation of *ortho*-hydroxy derivatives. Kinetic studies have resulted in much mechanistic information being deduced from the structural changes in the azoxybenzene<sup>6</sup> and azoxynaphthalene series,<sup>7</sup> but extension of such studies to the heterocyclic azoxy compounds has not been systematically reported. Only the phenylazoxypyridines and their *N*-oxides were investigated by Buncl and his coworkers.<sup>8</sup> We set out to extend the generic Wallach rearrangement to heterobicyclic ring systems, and started our investigations with azoxyquinoxaline **3**;<sup>9</sup> this revealed some interesting and surprising reactions and products, depending on the reaction media. This short paper reports our findings.



**Scheme 1.** Wallach rearrangement.

## Results and Discussion

We first applied the original Wallach rearrangement conditions, treating azoxy compound **3** with conc. sulfuric acid in the expectation of obtaining the corresponding 3-oxo (*ortho*-like product, **4a**) or 6-hydroxy (*para*-like product, **4b**) azo compound (Scheme 2).




**Scheme 2.** Expected reaction of **3** in conc. sulfuric acid.

Buncel and his coworkers reported that the phenylazoxy pyridines and their *N*-oxides react much more slowly than does azoxybenzene itself, presumably because of the extra positive charge present in the substrates.<sup>8</sup> We therefore decided to carry out the transformation of **3** at higher temperature. After azoxyquinoxaline **3** had been stirred in conc. sulfuric acid at 140 °C for 10 min, the isolated product was recrystallized and characterized by HRMS assay. Surprisingly, we observed nitrous gas evolution and, consistently, HRMS assay did not contain any O atom: instead of the Wallach rearrangement, formally “HNO” was eliminated from **3**. Compound **5**, with the molecular formula C<sub>16</sub>H<sub>9</sub>N<sub>5</sub>, was obtained in 63% yield (Scheme 3). On the basis of 2D NMR measurements, a new pentacyclic system, imidazo[1,2-*a*:4,5-*b*]diquinoxaline **5**, is proposed for the structure.

This structure was supported by an independent synthesis starting from 2,3-dichloroquinoxaline **6** and 2-aminoquinoxaline **7**, subjected to the Buchwald-Hartwig protocol,<sup>10</sup> yielding compound **5** in 43%. The synthesis was also carried out in a two-step reaction. The

nucleophilic substitution of compound **6** with amine **7** gave 1-(3'-chloro-2'-quinoxaliny)quinoxalin-2(1*H*)-imine **8**, which underwent the Buchwald-Hartwig cyclization<sup>10</sup> to yield pentacyclic compound **5**.



**Scheme 3.** Formation of **5**.

**Table 1.** Influence of the nature of the acid and temperature on the transformation of **3**

Entry	Medium	$pK_a$	$T$ [ $^\circ\text{C}$ ]	Product	Yield [%] <sup>a</sup>
1	conc. $\text{H}_2\text{SO}_4$	-3.0	140	<b>5</b>	63
2	conc. $\text{H}_2\text{SO}_4$	-3.0	r.t.	<b>5</b>	67 <sup>b</sup>
3	$\text{CH}_3\text{SO}_3\text{H}$	-2.6	140	<b>5</b>	56
4	$\text{CF}_3\text{COOH}$	-0.25	72 <sup>c</sup>	<b>5</b>	56
5	$\text{HCOOH}$	3.77	101 <sup>c</sup>	<b>5</b>	67
6	$\text{AcOH}$	4.76	118 <sup>c</sup>	<b>12</b>	85
7	$\text{Ac}_2\text{O}$	-	140 <sup>c</sup>	<b>12</b>	87
8	glycol	-	140	<b>12</b>	80
9	morpholine	-	129 <sup>c</sup>	<b>16</b>	87

<sup>a</sup>Reaction time 10 min; yield after isolation and recrystallization.


<sup>b</sup>Reaction time 48 h.

<sup>c</sup>At boiling temperature.

Various strong mineral and organic acids uniformly furnished **5** (Table 1, Entries 1-5). In the presence of sulfuric acid, a reduction of the temperature did not have a significant influence on


the nature or quantity of the product, but the necessary reaction time increased considerably, from 10 min to 48 h (Entry 2).

A possible formation of pentacyclic derivative **5** is depicted in Scheme 4. In the protonated form **9**, 1,2-aryl migration occurred on the diazo moiety, followed by "HNO" loss to give a di(quinoxalin-2-yl)amino cation **10**. Then the pentacyclic skeleton **11** was formed by electrocyclization of **10**, and after deprotonation pentacycle **5** was obtained.




**Scheme 4.** Proposed mechanism of the acid catalyzed reaction of **3**.

When the value of  $pK_a$  was systematically increased, dramatic changes were observed above  $pK_a$  3.77. Reaction in boiling acetic acid provided **12** instead of **5** (Entry 6, Scheme 5). The HRMS assay indicated the elimination of  $\text{N}_2$  from **3** to yield quinoxalinyloquinolone **12**. Its structure was proved by X-ray crystallography: the relative positions of the two planar quinoxaline rings are characterized by a C12-N11-C3-C2 of a torsion angle of  $63.2(2)^\circ$  (Figure 1).<sup>11</sup> Quinoxalinyloquinolone **12** was earlier isolated by Iijima: heating of quinoxaline *N*-oxide with acetic anhydride resulted in formation **12** (4%) among others.<sup>12</sup>



**Scheme 5.** Proposed mechanism of the thermal reaction of **3**.




**Figure 1.** Structure of compound **12** with the crystallographic atomic numbering.

The question arose of the possibility of thermal reaction; the same product was obtained from neutral organic solvents (Entries 7 and 8) and even neat from **3**. Accordingly, we carried out thermoanalytical studies (DSC, TG and DTG). At the melting point of **3**, an intense exothermic reaction ( $\mathbf{3} \rightarrow \mathbf{12}$ ,  $\Delta H_{166^\circ\text{C}} = 84.6$  kcal/mol) was detected, and the gravimetry demonstrated a relative loss of mass  $\Delta m_{172^\circ\text{C}} = 9.3\%$ , which is consistent with N<sub>2</sub> elimination (theoretical loss:  $\Delta m = 9.3\%$ ). When the same sample (now containing quinoxalinyloquinone **12**) was further heated to 220 °C, endothermic melting ( $\Delta H_{220^\circ\text{C}} = 7.2$  kcal/mol) ensued. In solvents, the N<sub>2</sub> elimination proceeded even at lower temperatures, indicating a very strong solvent effect (Entries 6-8). This type of thermal transformation does not appear to have been widely described

in the literature: only one example of the thermolytic loss of N<sub>2</sub> from azoxy compounds is known.<sup>13</sup>

On the evidence of these studies and the literature data, we propose the mechanistic pathway depicted in Scheme 5. The first step involves *ipso*-attack by the oxygen of the azoxy moiety of **3** on the positively charged C2 of the more distant quinoxaline ring to furnish *spiro* derivative **13**. This is followed by a [2+2]-cycloreversion of intermediate **13** to give quinoxalinone anion **14** and quinoxaline-3-diazonium ion **15**. N<sub>2</sub> loss occurred during recombination of cation **15** and anion **14** providing quinoxalinyloxyquinoxalinone **12**.

To find support for the proposed mechanism we attempted to trap cationic species by a nucleophile. In view of the scope and limitations of the trapping reaction, we set out to catch cation **15** in morpholine. When **3** was heated in boiling morpholine, 2-(morpholin-4-yl)quinoxaline **16** was obtained in good yield (Entry 9, Scheme 6).<sup>14</sup> Similar treatment of **12** for 10 min resulted in the formation of < 1% of **16**.



**Scheme 6.** Formation of **16**.

## Conclusions

In summary, the treatment of azoxy compound **3** with strong acids or thermally led to two different reaction pathways, furnishing pentacyclic system **5** and quinoxalinyloxyquinoxalinone **12**. The structures of the products were supported by detailed NMR analysis, and confirmed by independent synthesis (for **5**) and X-ray crystallography (for **12**). A possible interpretation of the formations of products **5** and **12** is proposed.

## Experimental Section

**General.** Melting points were determined in open capillary tubes with a Büchi 535 apparatus and are uncorrected. NMR spectra were measured with a Bruker Avance 500, Avance 400 or Avance 200 instrument, mass spectra (GC-MS) with a Shimadzu GCMS-QP2010S instrument, high-resolution mass spectra with a Waters LCT Premier XE instrument, and IR spectra with a VERTEX 70 instrument (KBr).

***N,N'*-Di(quinoxalin-2-yl)diazene *N*-oxide (3).** Compound **3** was prepared as described in method b) in ref. 9. The product was found to be identical.

**Imidazo[1,2-*a*:4,5-*b'*]diquinoxaline (5)**

**Method A.** A suspension of **3** (300 mg, 1 mmol) in conc. sulfuric acid (1 mL) was stirred at 140 °C for 10 min. The reaction mixture was then cooled to room temperature and poured into NaHCO<sub>3</sub> solution, after which the precipitate was filtered off. The crude product was recrystallized from methanol. Yield 171 mg, 63%; orange crystals (from methanol); mp 243-245 °C.

**Method B.** A solution of **8** (308 mg, 1 mmol), sodium *tert*-butoxide (198 mg, 2 mmol), phosphine ligand **L** (22 mg, 0.05 mmol) and Pd<sub>2</sub>dba<sub>3</sub> (46 mg, 0.05 mmol) in *tert*-butanol (2 mL) was stirred at 70 °C for 24 h. The reaction mixture was cooled to room temperature and was purified by prep. TLC (Kieselgel 60 F<sub>254</sub>, 2 mm, toluene : methanol = 4 : 1). The product was recrystallized from methanol. Yield 214 mg, 79%; orange crystals (from methanol); mp 244-245 °C.

**Method C.** A solution of **6** (207 mg, 1 mmol), **7** (160 mg, 1.1 mmol), sodium *tert*-butoxide (218 mg, 2.2 mmol), phosphine ligand **L** (22 mg, 0.05 mmol) and Pd<sub>2</sub>dba<sub>3</sub> (46 mg, 0.05 mmol) in *tert*-butanol (2 mL) was stirred at 70 °C for 24 h. The reaction mixture was cooled to room temperature and was purified by prep. TLC (Kieselgel 60 F<sub>254</sub>, 2 mm, toluene : methanol = 4 : 1). The product was recrystallized from methanol. Yield 117 mg, 43%; orange crystals (from methanol); mp 244-245 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 27 °C) δ 9.57 (d, <sup>3</sup>J<sub>H,H</sub> = 8.2 Hz, 1 H, 1-H), 9.37 (s, 1 H, 6-H), 8.37 and 8.34 (m, 2 H, 12-H and 9-H), 8.18 (d, <sup>3</sup>J<sub>H,H</sub> = 8.0 Hz, 1 H, 4-H), 7.88 and 7.86 (m, 3 H, H-10, H-11 and 2-H), 7.66 (dd, <sup>3</sup>J<sub>H,H</sub> = 8.0 Hz, <sup>3</sup>J<sub>H,H</sub> = 7.4 Hz, 1 H, 3-H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, 27 °C): δ 148.9 (7a-C), 146.1 (6a-C), 146.0 (6-C), 142.9 (8a-C or 12a-C), 140.0 (8a-C or 12a-C), 138.2 (13a-C), 135.2 (4a-C), 131.5 (2-C), 130.9 (4-C), 129.8 (9-C or 12-C), 129.4 (10-C or 11-C), 129.3 (10-C or 11-C), 128.8 (9-C or 12-C), 128.1 (13c-C), 126.7 (3-C), 116.9 (1-C); MS(EI+) *m/z* = 271 [M<sup>+</sup>], 244, 143, 129; HRMS(ES+) *m/z* = 272.0919 [MH<sup>+</sup>], calcd. for C<sub>16</sub>H<sub>10</sub>N<sub>5</sub><sup>+</sup> 272.0936.

**1-(3'-Chloro-2'-quinoxaliny)quinoxalin-2(1H)-imine (8).** A solution of **6** (218 mg, 1.05 mmol), **7** (145 mg, 1 mmol) and potassium *tert*-butoxide (118 mg, 1 mmol) in DMSO (1.5 mL) was stirred at room temperature for 3 h. The reaction mixture was poured into water (7.5 mL), the precipitate was filtered off. The crude product was recrystallized from acetonitrile. Yield 103 mg, 33%; purity: 83% (HPLC); yellow crystals (from acetonitrile); mp 196 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 27 °C) δ 10.17 (br, 1 H, NH), 9.57 (br, 1 H, 3-H), 8.06 (d, <sup>3</sup>J<sub>H,H</sub> = 8.4 Hz, 1 H, 5-H), 7.96 (d, <sup>3</sup>J<sub>H,H</sub> = 8.0 Hz, 1 H, 5'-H), 7.90 and 7.88 (m, 2 H, 8-H and 8'-H), 7.80 and 7.79 (m, 2 H, 7-H and 7'-H), 7.71 and 7.69 (m, 2 H, 6-H and 6'-H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 27 °C) δ 148.4 (2-C), 145.4 (2'-C or 4a'-C), 141.3 (br, 3-C), 140.8 (8a-C), 140.3 (3'-C), 139.4 (8a'-C), 138.9 (4a-C), 138.1 (4a'-C or 2'-C), 131.0 (7'-C), 130.7 (7-C), 128.9 (5-C), 128.0 (6'-C), 127.8 (6-C), 127.75 (5'-C), 127.1 (br, 8-C), 126.8 (8'-C); MS(EI+) *m/z* = 271 [M-HCl]<sup>+</sup>, 143, 129, 102; HRMS(ES+) *m/z* = 308.0707 [MH<sup>+</sup>], calcd. for C<sub>16</sub>H<sub>11</sub>ClN<sub>5</sub><sup>+</sup> 308.0703.

**1-(Quinoxalin-2-yl)quinoxalin-2(1H)-one (12).** A suspension of **3** (300 mg, 1 mmol) in acetic anhydride (1 mL) was stirred at the boiling point for 10 min. The reaction mixture was then cooled to room temperature and poured into NaHCO<sub>3</sub> solution, after which the precipitate was filtered off. The crude product was recrystallized from methanol. Yield 238 mg, 87%; yellow crystals; mp 222-223 °C (lit.<sup>12</sup> mp 218 °C); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 27 °C) δ 9.20 (s, 1 H, 3'-H), 8.44 (s, 1 H, 3-H), 8.30 (d, <sup>3</sup>J<sub>H,H</sub> = 8.1 Hz, 1 H, 5'-H), 8.20 (d, <sup>3</sup>J<sub>H,H</sub> = 7.8 Hz, 1 H, 8'-H), 8.06 and 8.02 (m, 2 H, 6'-H and 7'-H), 7.96 (d, <sup>3</sup>J<sub>H,H</sub> = 7.6 Hz, 1 H, 5-H), 7.48 and 7.44 (m, 2 H, 7-H and 6-H), 6.92 (d, <sup>3</sup>J<sub>H,H</sub> = 8.1 Hz, 1 H, 8-H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 27 °C) δ 154.7 (2-C), 151.3 (3-C), 146.1 (3'-C), 145.0 (2'-C), 142.2 (4a'-C), 141.5 (8a'-C), 132.8 (8a-C), 132.7 (4a-C), 132.2 (6'-C), 131.8 (7'-C), 131.6 (7-C), 130.1 (5-C), 129.5 (2 C, 5'-C and 8'-C), 124.8 (6-C), 115.8 (8-C); MS(EI+) *m/z* = 274 [M<sup>+</sup>], 273, 245, 219; HRMS(ES+) *m/z* = 275.0927 [MH<sup>+</sup>], calcd. for C<sub>16</sub>H<sub>11</sub>N<sub>4</sub>O<sup>+</sup> 275.0933; IR(KBr) 1667cm<sup>-1</sup> (ν<sub>amide C=O</sub>).

**2-(Morpholin-4-yl)quinoxaline (16).** A solution of **3** (300 mg, 1 mmol) in morpholine (1 mL) was stirred at the boiling point for 10 min. The reaction mixture was then cooled to room temperature and purified by prep. TLC (Kieselgel 60 F<sub>254</sub>, 2 mm, hexane : EtOAc = 1 : 1). The product was recrystallized from methanol. Yield 187 mg, 87%; red crystals; mp 85-87 °C (lit.<sup>14</sup> mp 88-89 °C); <sup>1</sup>H NMR (200 MHz, DMSO-*d*<sub>6</sub>, 27°C) δ 8.81 (s, 1 H, 3-H), 7.84 (d, <sup>3</sup>J<sub>H,H</sub> = 8.2 Hz, 1 H, 5-H), 7.64-7.54 (m, 2 H, 8-H and 7-H), 7.47-7.43 (m, 1 H, 6-H), 3.73 (br, 8 H, 2'-H and 3'-H); <sup>13</sup>C NMR (50 MHz, DMSO-*d*<sub>6</sub>, 27 °C) δ 152.6 (2-C), 141.4 (8a-C), 137.2 (3-C), 136.8 (4a-C), 130.4 (7-C), 128.8 (5-C), 126.5 (8-C), 125.0 (6-C), 66.3 (2 C, 2'-C), 44.9 (2 C, 3'-C); MS(EI+) *m/z* = 215 [M<sup>+</sup>], 184, 158, 130, 102; HRMS(ES+) *m/z* = 216.1120 [MH<sup>+</sup>], calcd. for C<sub>12</sub>H<sub>14</sub>N<sub>3</sub>O<sup>+</sup> 216.1137; IR(KBr) 2926 cm<sup>-1</sup>, 2858 cm<sup>-1</sup>.

## Acknowledgements

We are grateful David Durham for the linguistic improvement of the manuscript. One of the authors (A.M.) expresses her thanks for support through a Sanofi Aventis Fellowship.

## References

1. Selected reviews: (a) Schündehütte, K. H. In *Houben-Weyl*; Stroh, R. Ed.; Thieme: Stuttgart, 1965; Vol. 10/3, p 771. (b) Buncl, E. In *Mechanisms of Molecular Migrations*; Thyagarajan, B. S. Ed.; Interscience: New York, 1968; Vol. 1, p 61. (c) Cox, R. A.; Buncl, E. In *The Chemistry of Hydrazo, Azo and Azoxy Groups*; Patai, S. Ed.; Wiley: New York, 1975; Vol. 2; p 808. (d) Özen, A. S.; Erdem, S. S.; Aviyente, V. *Struct. Chem.* **1998**, *9*, 15.
2. Wallach, O.; Belli, L. *Chem. Ber.* **1880**, *13*, 525.



3. (a) Baudisch, O.; Fürst, R. *Chem. Ber.* **1912**, *45*, 3426. (b) Cumming, W. M.; Ferrier, G. S. *J. Chem. Soc. Abst.* **1925**, *127*, 2374. (c) Badger, G. M.; Buttery, R. G. *J. Chem. Soc.* **1953**, 2156.
4. Yamato, J.; Nishigaki, Y.; Umezu, M.; Matsuura, T. *Tetrahedron* **1980**, *36*, 3177.
5. Singh, J.; Singh, P.; Boivin, J. L.; Gagnon, P. E. *Can. J. Chem.* **1963**, *41*, 499.
6. (a) Duffey, D.; Hendley, E. C. *J. Org. Chem.* **1968**, *33*, 1918. (b) Stevens, T. E. *J. Org. Chem.* **1968**, *33*, 2667. (c) Hendley, E. C.; Duffey, D. *J. Org. Chem.* **1970**, *35*, 3579. (d) Keum, S. R.; Lee, H. I. *J. Korean Chem. Soc.* **1993**, *37*, 148.
7. (a) Cox, R. A.; Dolenko, A. J.; Buncel, E. *J. Chem. Soc., Perkin Trans. 2* **1975**, *53*, 471. (b) Buncel, E.; Cox, R. A.; Dolenko, A. J. *Tetrahedron Lett.* **1975**, *3*, 215.
8. (a) Buncel, E.; Keum, S. R. *J. Chem. Soc., Chem. Commun.* **1983**, 578. (b) Buncel, E.; Keum, S. R.; Rajagopal, S.; Klepek, E. *Can. J. Chem.* **2008**, *86*, 298.
9. Harsányi, K.; Gönczi, Cs.; Korbonits, D. *Justus Liebigs Ann. Chem.* **1973**, *2*, 190.
10. (a) Loones, K. T. J.; Maes, B. U. W.; Dommissie, R. A.; Lemièrre, G. L. F. *Chem. Commun.* **2004**, 2466. (b) Loones, K. T. J.; Maes, B. U. W.; Dommissie, R. A. *Tetrahedron* **2007**, *63*, 8954. (c) Bogányi, B.; Kámán, J. *J. Heterocycl. Chem.* **2009**, *46*, 33.
11. CCDC-749526 contains the supplementary crystallographic data for compound **12**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via [www.ccdc.cam.ac.uk/data\\_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif).
12. Iijima, C. *Yakugaku Zasshi* **1967**, *87*, 942.
13. (a) Moskalenko, G. G.; Sedova, V. F.; Mamaev, V. P. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1987**, 701. (b) Moskalenko, G. G.; Sedova, V. F.; Mamaev, V. P. *Bull. Acad. Sci. USSR, Div. Chem. Sci. (English Trans.)* **1987**, *36*, 642.
14. Iijima, C.; Kyō, T. *Chem. Pharm. Bull.* **1989**, *37*, 618.